Peppermint Gut Motility Meta-Analysis Evidence Table

Structured evidence table for Peppermint Gut Motility Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Peppermint Gut Motility Meta-AnalysisYoung adults, particularly females, have a higher prevalence, which has increased substantially over the past decades [].2Pastras Ploutarchos (2026)Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines
Peppermint Gut Motility Meta-AnalysisMore specifically, the presence of recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following: symptoms related to defecation, a change in stool frequency, or a change in stool form [].2Pastras Ploutarchos (2026)Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines
Peppermint Gut Motility Meta-AnalysisIBS is associated with reduced engagement in daily activities, increased work absenteeism, and impaired functioning, thereby increasing the global healthcare burden [].2Pastras Ploutarchos (2026)Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines
Peppermint Gut Motility Meta-Analysis1 2 1 3 1 4 5 Disorders of gut–brain interaction (DGBIs) are functional gastrointestinal conditions characterized by a complex interplay between the gut and the brain [].2Pastras Ploutarchos (2026)Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines
Peppermint Gut Motility Meta-Analysis1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities [].3Šuran Jelena (2026)IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
Peppermint Gut Motility Meta-AnalysisEarly studies reported SIBO in up to 60–78% of IBS cases based on lactulose breath testing [,,], though later investigations using more rigorous methods found lower prevalences (e.g., 4–20%) [,].3Šuran Jelena (2026)IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
Peppermint Gut Motility Meta-AnalysisMoreover, increasing evidence implicating the gut microbiota in IBS/SIBO has spurred interest in interventions that modulate microbial communities.3Šuran Jelena (2026)IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
Peppermint Gut Motility Meta-AnalysisIt affects an estimated 5–10% of the global population and is more common in women, imposing a significant burden on quality of life and healthcare resources [].3Šuran Jelena (2026)IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
topicPeppermint Gut Motility Meta-Analysis
claimYoung adults, particularly females, have a higher prevalence, which has increased substantially over the past decades [].
evidence level2
citationPastras Ploutarchos (2026)
sourcePlant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines
topicPeppermint Gut Motility Meta-Analysis
claimMore specifically, the presence of recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following: symptoms related to defecation, a change in stool frequency, or a change in stool form [].
evidence level2
citationPastras Ploutarchos (2026)
sourcePlant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines
topicPeppermint Gut Motility Meta-Analysis
claimIBS is associated with reduced engagement in daily activities, increased work absenteeism, and impaired functioning, thereby increasing the global healthcare burden [].
evidence level2
citationPastras Ploutarchos (2026)
sourcePlant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines
topicPeppermint Gut Motility Meta-Analysis
claim1 2 1 3 1 4 5 Disorders of gut–brain interaction (DGBIs) are functional gastrointestinal conditions characterized by a complex interplay between the gut and the brain [].
evidence level2
citationPastras Ploutarchos (2026)
sourcePlant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines
topicPeppermint Gut Motility Meta-Analysis
claim1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities [].
evidence level3
citationŠuran Jelena (2026)
sourceIBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
topicPeppermint Gut Motility Meta-Analysis
claimEarly studies reported SIBO in up to 60–78% of IBS cases based on lactulose breath testing [,,], though later investigations using more rigorous methods found lower prevalences (e.g., 4–20%) [,].
evidence level3
citationŠuran Jelena (2026)
sourceIBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
topicPeppermint Gut Motility Meta-Analysis
claimMoreover, increasing evidence implicating the gut microbiota in IBS/SIBO has spurred interest in interventions that modulate microbial communities.
evidence level3
citationŠuran Jelena (2026)
sourceIBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
topicPeppermint Gut Motility Meta-Analysis
claimIt affects an estimated 5–10% of the global population and is more common in women, imposing a significant burden on quality of life and healthcare resources [].
evidence level3
citationŠuran Jelena (2026)
sourceIBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions

Source documents

  1. Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines
  2. IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions